Search
for
Sort by
Research 301–330 of 529
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- <i>IKZF1</i> and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Effects of Natural Herbal Marker Compounds on Human Dermal Papilla Cell Growth Regulation
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- 1432 IL-9/IL-9R signaling as a novel regulator of human hair follicle growth and immune privilege
- A perspective on predictive markers of alopecia
- 865 Frontal fibrosing alopecia is associated with dysregulation of cholesterol biosynthesis pathways, fibrosis and mast cells
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- The JAK/STAT signaling pathway: from bench to clinic
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Skin Pigmentation Types, Causes and Treatment—A Review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results